Genomtec S.A. — Regulatory Filings 2022

Aug 10, 2022

Signing of commercial partnership agreement for Genomtec_#174; ID sales inTaiwan.The Management Board of Genomtec S.A. (_quot;Issuer_quot;,_quot;Company_quot;) announces that today, i.e., 10 August 2022, it signed anagreement (the _quot;Agreement_quot;) with a Commercial Partner, a Companyoperating in Poland with its subsidiary headquartered in Taipei, Taiwan(the _quot;Partner_quot;), pertaining business opportunities identification thatshould lead to local commercial agreements signing for market adoptionof the Genomtec_#174; ID platform (the "Product") in Taiwan (the"Territory"). Pursuant to the Agreement, the Partner will support theIssuer qualifying the leads and their propensity in signing commercialagreements for distributorship, wholesale, re-sale of the Products onthe Territory, along with Partner's in-field marketing activities, andregulatory consulting for the Product sales authorisation in theTerritory.The Partner is a renowned innovative, Polish-Japanesebiotechnology firm that specialises in the go-to-market strategyespecially for South Asia, focusing on the nutraceuticals and medicaldiagnostics devices. In addition to diagnostics, Partner's activitiesfocus on R_amp;D and commercialization of innovative solutions in the fieldof biotechnology. The Partner operates internationally, working closelywith top Japanese and Taiwanese suppliers and experts in the field ofbiotechnology.The Company's Management Board considered the factof concluding the Agreement to be confidential information, as theimplementation of the aforementioned Agreement may have a significantimpact on the Issuer's future revenue situation, as well as on thepopularization of the Company's technology and Product. Therefore, thisinformation, in the opinion of the Management Board, meets the criteriafor confidential information within the meaning of Article 17 (1) of MAR.